Korean J Reprod Med Search


Korean Journal of Reproductive Medicine 2010;37(1):41-48.
Published online March 1, 2010.
Sequential use of Intramuscular and Oral Progesterone for Luteal Phase Support in in vitro Fertilization.
Sang Don Kim, Byung Chul Jee, Jung Ryeol Lee, Chang Suk Suh, Seok Hyun Kim, Shin Yong Moon
1Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital, Korea.
2Department of Obstetrics and Gynecology, College of Medicine, Seoul National University, Korea.
OBJECTIVES: The aim of this study was to assess appropriate time to convert intramuscular progesterone support to oral administration for luteal phase support in in vitro fertilization (IVF). METHODS: Seventy-six cycles of IVF in which fetal heart beat was identified after treatment were included. Patients underwent controlled ovarian hyperstimulation with GnRH agonist long protocol (n=7) or GnRH antagonist protocol (n=66). Cryopreserved embryo transfer was performed in three cycles. Luteal support was initiated by daily intramuscular injection of progesterone, and after confirmation of fetal heart beat, converted to oral micronized progesterone (Utrogestan, Laboratoires Besins International, France) 300 mg daily before or after 8 gestational weeks. The oral progesterone was continued for 11 weeks. RESULTS: Overall clinical abortion rate was 3.9% (3/76) and mean time to conversion was 8(+4) gestational weeks (46+/-5.8 days after oocytes retrieval). The abortion rate was 5.6% (1/17) and 3.4% (2/59) in patients with conversion before 7 weeks and after 8 weeks, respectively, which were not statistically significant (p=0.678). The miscarriages were occurred at 9(+4) weeks, 11(+3) weeks and 11(+4) weeks. CONCLUSION: Sequential luteal support using intramuscular and oral progesterone yields a relatively low clinical abortion rate. If fetal heart beat confirmed, sequential regimen appears to be safe and convenient method to reduce patients' discomfort induced by multiple injections.
Key Words: Luteal phase support; Oral progesterone; In vitro fertilization


Browse all articles >

Editorial Office
Department of Obstetrics and Gynecology CHA Bundang Medical Center, CHA University
59 Yatap-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, Korea
Tel: +82-31-727-8701    CP: +82-10-9072-3154    E-mail: hwas0605@cha.ac.kr                

Copyright © 2022 by Korean Society for Reproductive Medicine.

Developed in M2PI

Close layer
prev next